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Background: This randomised, double-blind, four-way, crossover, Phase II study compared the
24-h forced expiratory volume in 1 s (FEV1) profile of alternative dosing frequencies of two
total daily doses of olodaterol (5 and 10 mg) in patients with chronic obstructive pulmonary
disease (COPD).
Methods: Patients received olodaterol 2 mg twice daily (BID), 5 mg BID, 5 mg once daily (QD) and
10 mg QD in a randomised sequence over 3-week treatment periods. Co-primary end pointsC0e12, area under the curve from 0 to 12 h; AUC0e24, area under the curve from 0 to 24 h; AUC12e24,
ID, twice daily; CI, confidence interval; COPD, chronic obstructive pulmonary disease; Cpre,ss, plasma
, plasma concentration at 10 min post-dosing; FEV1, forced expiratory volume in 1 s; FVC, forced vital
t; QD, once daily.
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Once-daily vs twice-daily olodaterol in COPD 607were FEV1 area under the curve from 0 to 12 h (AUC0e12) and area under the curve from 12 to
24 h (AUC12e24) responses. Additional lung-function responses, pharmacokinetics and safety
were assessed.
Results: 47 patients were treated. All olodaterol doses provided significant increases in FEV1
versus baseline (p < 0.001) and FEV1 time profiles were nearly identical for olodaterol 5 and
10 mg QD. Olodaterol 5 mg QD demonstrated improved FEV1 AUC0e12 and similar AUC12e24 versus
2 mg BID. Olodaterol 5 mg QD showed slightly increased FEV1 AUC0e12 but lower AUC12e24
compared to 5 mg BID. Bronchodilation over 24 h was similar for olodaterol 5 mg QD and BID.
All doses were well tolerated.
Conclusions: Olodaterol 5 mg QD is efficacious in COPD, with a superior bronchodilatory profile
compared to 2 mg BID, which is close to the same total daily dose, and a similar degree of
bronchodilation over 24 h compared with double the daily dose (administered as 10 mg QD
or 5 mg BID).
Trial registration: ClinicalTrials.gov: NCT00846768.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terised by non-reversible airflow limitation and a progres-
sive deterioration in lung function [1e4]. b2-adrenoceptor
agonists are among the most potent rapidly acting bron-
chodilators, providing therapeutic benefits in the treat-
ment of COPD [5]. The first generation of long-acting b2-
agonists (LABAs), which include salmeterol and formoterol,
have a 12-h duration of action and consequently require
twice-daily (BID) dosing to ensure effective bronchodilation
over 24 h [5]. More recently, LABAs with a longer duration
of action have been developed [6] allowing for once-daily
(QD) dosing, which may improve treatment adherence in
patients with COPD [7].
Olodaterol is a novel, enantiomerically pure, selective
LABA [8]. The preclinical profile of olodaterol shows that it
has high selectivity for the human b2-adrenoceptor, with a
potent, near full-agonist response in vitro, and provides
effective bronchoprotection over 24 h in anaesthetised
guinea pigs and dogs in vivo [9]. Together, these data sug-
gested that 24-h bronchodilation may be achieved with QD
administration in humans.
Single-dose administration of olodaterol has been shown
to provide effective bronchodilation over 24 h in patients
with COPD [4] and effective bronchoprotection against
inhaled methacholine for up to 32 h in patients with asthma
[10].
The study presented here is one of two trials designed to
determine the optimum dose and frequency of olodaterol in
patients with COPD. In a 4-week Phase II study
(NCT00452400) evaluating the bronchodilatory efficacy of
four QD doses of olodaterol (2, 5, 10 and 20 mg), olodaterol
10 and 20 mg QD were shown to be on the plateau of the
doseeresponse curve, while olodaterol 2 mg QD was on the
steep part of the curve [11]. This report describes the other
Phase II study, which was designed to further evaluate the
bronchodilatory activity of olodaterol by comparing the 24-
h forced expiratory volume in 1 s (FEV1) profiles of QD
olodaterol (5 mg and 10 mg) and BID olodaterol (2 mg and
5 mg) dosing regimens following 3 weeks of treatment inpatients with COPD. The 5 mg and 10 mg QD doses were
selected for further evaluation in long-term Phase III
studies, which have now demonstrated 24-h efficacy and
satisfactory tolerability in patients with moderate to very
severe COPD [12e15].
Methods
Patients
Patients were enrolled into the study if they met the
following inclusion criteria: age  40 years; current or ex-
smokers with a smoking history of > 10 pack-years; post-
bronchodilator FEV1 < 80% of predicted normal; and post-
bronchodilator FEV1/forced vital capacity (FVC) < 70%.
Key exclusion criteria were: a significant disease other than
COPD (defined by the investigator as a disease that may put
the patient at risk by participating in the study, influence
study outcomes or cause concern with regards to the pa-
tient’s ability to participate in the study); history of
asthma; history of myocardial infarction within 1 year of
the screening visit; unstable or life-threatening cardiac
arrhythmia or hospitalisation for heart failure within the
past year; or experience of any respiratory infection or
COPD exacerbation 6 weeks prior to initiation of the study
or during the baseline period.
Study design
This was a Phase II, randomised, double-blind, four-way,
crossover study (registered with ClinicalTrials.gov:
NCT00846768). Patients completed a pre-treatment base-
line 24-h FEV1 profile and then were randomly assigned into
four groups to receive each of the following treatments in a
randomised sequence: olodaterol 2 mg BID, 5 mg BID, 5 mg
QD and 10 mg QD. Each administration of olodaterol
comprised two actuations of the Respimat inhaler. Each
treatment period lasted for 3 weeks, with no washout in
between. Patients were evaluated for 14 days following
completion of the study (Fig. 1).
Figure 1 Study design.
608 G.F. Joos et al.Patients were permitted to use inhaled corticosteroids
and short-acting anticholinergics throughout the study, as
needed, and salbutamol (100 mg) was administered as
rescue medication, if required.
The study was approved by local ethics committees and
carried out according to the Declaration of Helsinki and
local regulations. Prior to study initiation, the protocol was
approved by the local Institutional Review Board, Inde-
pendent Ethics Committee and the Competent Authority.
All patients provided written, informed consent prior to the
study commencing.
Assessments
FEV1 was the primary criterion for evaluation in this study.
All qualifying pulmonary function tests (FEV1 and FVC) were
conducted during the screening visit. One week following
the initial screening visit, and appropriate washout for
bronchodilators, all patients underwent pulmonary func-
tion testing over 24 h to determine the pre-treatment
baseline 24-h FEV1 time profile. FEV1 and FVC pulmonary
function tests were performed at the end of each 3-week
treatment period (Visits 2e6). Pulmonary function tests
were always started at approximately the same time of day
for each patient. All spirometry was performed according
to American Thoracic Society/European Respiratory Society
criteria [16]. Daily trial medication and daily rescue medi-
cation use (salbutamol 100 mg per actuation) were recorded
in paper diaries for assessment of adherence.
Safety measurements included laboratory tests, vital
signs (blood pressure and pulse rate) and 12-lead electro-
cardiogram. All adverse events (AEs), irrespective of cau-
sality, were recorded at each visit.
Plasma concentrations of olodaterol were assessed by
taking 9e10 mL of blood from a forearm vein prior to and
10 min after drug inhalation at the end of each 3-week
treatment period. Urine samples were collected from 0 to
12 and 12 to 24 h after dosing for the QD treatments, and
from 0 to 12 h after the morning and evening dose for the
BID doses at the end of each 3-week treatment period.
Plasma and urine concentrations were determined by vali-
dated methods using high-performance liquid chromatog-
raphy, coupled to tandem mass spectrometry.Study outcomes
The co-primary efficacy end points assessed were FEV1 area
under the curve from 0 to 12 h (AUC0e12) and FEV1 area
under the curve from 12 to 24 h (AUC12e24) responses from
baseline after 3 weeks of treatment. Secondary efficacy
variables included FEV1 area under the curve from 0 to 24 h
(AUC0e24), peak and trough FEV1 response following
3 weeks of treatment, corresponding FVC parameters, and
FEV1 and FVC measurements at individual time points over
a 24-h period (from which the FEV1 and FVC 24-h time
profiles could be constructed). Safety end points, including
AEs and vital signs, were assessed in all patients who
received at least one dose of the study drug. Pharmacoki-
netic parameters evaluated following 3 weeks of treatment
included the olodaterol plasma concentration prior to
dosing (Cpre,ss or ‘trough’) and at 10 min post-dosing
(C0.167,ss), and the fraction of olodaterol dose eliminated
in urine within the dosing interval.
Statistical analysis
A sample size of 48 randomised patients provided  90%
power to detect a difference between olodaterol and base-
line of 90 mL in FEV1 AUC0e12 and of 80 mL in FEV1 AUC12e24,
based on an estimated standard deviation of 0.16 L for FEV1
AUC0e12 and 0.14 L for FEV1 AUC12e24 and a conservative
estimated randomised discontinuation rate of 25%.
The primary and secondary efficacy end points were
based on the full analysis set, which included all patients
with baseline data and evaluable post-dosing data for at
least the co-primary end points. Both primary and second-
ary end points were analysed using a mixed-effects
repeated measures model with ‘treatment’ and ‘period’
as fixed effects and ‘period’ as a repeated effect, with
‘patient’ as the repeated subject and a compound sym-
metry covariance structure. The model did not contain
treatment sequence, as, owing to the trial design and half-
life of the study drug, there was no expectation that carry
over would occur.
Safety and pharmacokinetic analyses
All safety analyses were performed on the treated set,
which included all patients who received at least one dose
of the study drug. Analyses of AEs, laboratory data, vital
signs and pharmacokinetic parameters were descriptive in
nature. Pharmacokinetic parameters were determined by
non-compartmental analysis of the plasma/urine
concentration-time data using the WinNonlin software
(Professional, Version 5.2, Pharsight Corporation, Mountain
View, California, USA).
Results
Patient population
The trial was conducted from 16 February 2009 to 20 July
2009. A total of 56 patients at five centres in Belgium and
the Netherlands were enrolled into the study, 47 of whom
Figure 2 CONSORT diagram illustrating participant flow.
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was discontinued prematurely due to worsening of disease
(Fig. 2). There were a greater number of men than women
participating in the study, and patients had a mean age of
65.6 years, with a mean smoking history of 39.5 pack-years
(Table 1).
Efficacy
Lung function
All dosing regimens provided significant increases in the co-
primary end points of FEV1 AUC0e12 and AUC12e24 afterTable 1 Baseline patient demographics (treated set).
Patients, n (%) 47 (100.0)
Sex, n (%)
Male 36 (76.6)
Female 11 (23.4)
Mean (SD) age, years 65.6 (8.0)
Mean (SD) body mass index, kg/m2 26.2 (4.0)
Smoking status, n (%)
Ex-smoker 30 (63.8)
Current smoker 17 (36.2)
Mean (SD) smoking history, pack-years 39.5 (19.7)
Pre-bronchodilator, L
Mean (SD) FEV1 1.26 (0.32)
Mean (SD) % of predicted normal FEV1 45.1 (10.1)
Post-bronchodilator, L
Mean (SD) FEV1 1.44 (0.38)
Mean (SD) % of predicted normal FEV1 51.7 (12.0)
Mean (SD) change from
pre-bronchodilator FEV1
0.18 (0.15)
Mean (SD) post-bronchodilator FEV1/FVC, % 45.9 (8.8)
SD, standard deviation.3 weeks of treatment compared to baseline (p < 0.001)
(Table 2). The magnitude of response ranged from 0.155 L
(olodaterol 2 mg BID) to 0.209 L (olodaterol 5 mg QD) for
FEV1 AUC0e12, and 0.149 L (olodaterol 10 mg QD) to 0.201 L
(olodaterol 5 mg BID) for FEV1 AUC12e24. All dose regimens
also demonstrated significant increases in the secondary
end point of FEV1 AUC0e24 compared with baseline
(p < 0.001) (Table 2), ranging from 0.160 L (olodaterol 2 mg
BID) to 0.195 L (olodaterol 5 mg BID).
In addition, all dose regimens demonstrated increases in
FEV1 at all individual time points over the 24-h observation
period (Fig. 3a).
For comparisons across dosing regimens, the primary
focus was to compare olodaterol 5 mg QD with other QD and
BID regimens, since olodaterol 5 mg QD was the lowest QD
dose taken forward into the Phase III clinical programme.
2 mg BID versus 5 mg QD
The FEV1 AUC0e12 response for olodaterol 5 mg QD was
0.209 L compared with 0.155 L for olodaterol 2 mg BID,
while the FEV1 AUC12e24 response was 0.155 L (olodaterol
5 mg QD) and 0.167 L (olodaterol 2 mg BID). Over the com-
plete 24-h observation period, the FEV1 AUC0e24 response
was 0.182 L for olodaterol 5 mg QD compared with 0.160 L
for olodaterol 2 mg BID (difference Z 0.022 L, 95% confi-
dence interval [CI]: 0.005, 0.049) (Table 3; Fig. 3b).
5 mg QD versus 10 mg QD
Near identical FEV1 AUC0e12 responses of 0.209 L and
0.204 L were reported following treatment with olodaterol
5 mg QD and 10 mg QD. The FEV1 AUC12e24 response for
olodaterol 5 QD was 0.155 L compared with 0.149 L for
olodaterol 10 QD, while the FEV1 AUC0e24 responses were
0.182 L (olodaterol 5 mg QD) compared with 0.176 L (olo-
daterol 10 mg QD) (difference Z 0.006 L, 95% CI: 0.033,
0.021) (Table 3; Fig. 3c).
Table 2 Adjusted mean FEV1 AUC0e12 response, FEV1 AUC12e24 response and FEV1 AUC0e24 response after 3 weeks of treatment.
Doses Adjusted mean difference (standard error)
FEV1 AUC0e12, L FEV1 AUC12e24, L FEV1 AUC0e24, L
Baseline 1.187 (0.052) 1.132 (0.048) 1.160 (0.050)
Olodaterol 2 mg BID 0.155 (0.024) 0.167 (0.022) 0.160 (0.022)
Olodaterol 5 mg BID 0.189 (0.024) 0.201 (0.022) 0.195 (0.022)
Olodaterol 5 mg QD 0.209 (0.024) 0.155 (0.022) 0.182 (0.022)
Olodaterol 10 mg QD 0.204 (0.024) 0.149 (0.022) 0.176 (0.022)
Patients: 5 mg QD, nZ 47; 2 mg BID, nZ 46 (nZ 45; AUC0e12 and AUC0e24); 10 mg QD, nZ 46; 5 mg BID, nZ 46, p < 0.001 for all doses
versus baseline.
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FEV1 AUC0e12 responses of 0.209 L and 0.189 L were re-
ported following treatment with 5 mg QD and 5 mg BID,
respectively. The FEV1 AUC12e24 response for olodaterol
5 mg QD was 0.155 L compared with 0.201 L for olodaterol
5 mg BID. The FEV1 AUC0e24 response was 0.182 L for olo-
daterol 5 mg QD compared with 0.195 L for olodaterol 5 mg
BID (difference Z 0.013 L, 95% CI: 0.040, 0.014)
(Table 3; Fig. 3d).
As this was the first study to include BID doses of olo-
daterol, another comparison of interest was olodaterol 5 mg
BID compared with olodaterol 2 mg BID. There was a
consistent increase in the FEV1 response for olodaterol 5 mg
BID compared with olodaterol 2 mg BID over the full 24-h
observation period (Fig. 3e), with similar differences
observed in the FEV1 AUC0e12, FEV1 AUC12e24 and FEV1
AUC0e24 responses (0.033, 0.035 and 0.035 L, respectively)
(Table 3).
The comparisons across dosing regimens for FEV1 peak
response from 0 to 3 h were consistent with the results for
the FEV1 AUC0e12 response, while comparisons across
dosing regimens for trough FEV1 response were consistent
with the results for FEV1 AUC12e24 response (Table 4). Re-
sults for FVC responses were generally consistent with FEV1
responses (Fig. 4).
Pharmacokinetics
Trough plasma concentrations (Cpre,ss) of olodaterol 2 mg
BID and 5 mg QD were mostly below the limit of quantifi-
cation (2.0 pg/mL); therefore, the geometric mean for
these doses was not calculated. Trough plasma concen-
trations were measurable in more than one-third of pa-
tients following inhalation of olodaterol 5 mg BID and 10 mg
QD. Data showed that geometric mean values were com-
parable between both treatments (2.92 and 2.97 pg/mL,
respectively). The C0.167,ss olodaterol concentrations
following inhalation of 2 mg BID were mostly below the
limit of quantification; the geometric mean C0.167,ss values
for olodaterol 5 mg QD, 5 mg BID and 10 mg QD were 3.52,
4.28 and 5.78 pg/mL, respectively (Table 5). The fraction
of dose excreted via urine within the dosing interval was
similar across all dose groups (3.27e3.61%). The amount
of olodaterol excreted via urine within 24 h was similar
between 5 mg BID (340 ng) and 10 mg QD (343 ng), while
there was a slight difference in the daily amount of olo-
daterol excreted in urine between 2 mg BID (136 ng) and
5 mg QD (181 ng) due to the difference in total daily dose
(Table 5).Safety
Overall, 62% of patients experienced at least one AE
(Table 6), the majority of which were mild to moderate in
nature (only one patient receiving olodaterol 2 mg BID
experienced a serious AE of COPD exacerbation and pneu-
monia, which was not considered to be related to the study
drug). The most frequently reported AE was nasophar-
yngitis, which was reported by three patients (6.5%)
receiving 10 mg QD, three patients (6.5%) receiving 5 mg BID
and one patient (2.1%) receiving each of the 5 mg total daily
doses of olodaterol (Table 6). Drug-related AEs were re-
ported by seven patients (Table 7). Monitoring of other
safety parameters, including 12-lead electrocardiogram,
blood pressure, pulse rate and standard laboratory testing,
did not reveal any clinically relevant changes from baseline.Discussion
The results from this randomised, double-blind, four-way,
crossover study add to a growing body of evidence that QD
administration with olodaterol delivered by the Respimat
inhaler provides effective bronchodilation over a complete
24-h period in patients with COPD [4]. The study has also
provided new insights into the dose-response and dose-
frequency profile of olodaterol by comparing the 24-h
bronchodilatory profile of olodaterol when administered
as a QD (olodaterol 5 and 10 mg) or BID (olodaterol 2 and
5 mg) dosing regimen.
A comparison of the FEV1 time profiles for olodaterol
5 mg QD and olodaterol 2 mg BID (Fig. 3b) shows a separation
between the two dose regimens in the 0 to 12 h interval
similar to the separation observed for olodaterol 5 mg QD
and olodaterol 2 mg QD in the early daily dose-response
studies. The additional peak as a result of the second
evening dose of olodaterol 2 mg BID resulted in a similar
degree of bronchodilation for olodaterol 5 mg QD and olo-
daterol 2 mg BID in the 12 to 24 h interval. Thus, overall,
olodaterol 5 mg QD provided a superior bronchodilating
profile over 24 h compared with olodaterol 2 mg BID. One
potential limitation of the current study was the unavail-
ability of olodaterol 2.5 mg BID, as this dose of olodaterol
was not available in the Respimat device when the study
was initiated. Ideally, an olodaterol 2.5 mg dose would have
been included in this study to allow for direct comparison
between olodaterol 2.5 mg BID and 5 mg QD (i.e. the same
total daily dose). However, data calculated for a theoret-
ical 2.5 mg BID dose by interpolating between FEV1 values
Figure 3 Adjusted mean FEV1 AUC0e24 for olodaterol versus baseline after 3 weeks of treatment for: (a) all doses; (b) 5 mg QD and
2 mg BID; (c) 5 and 10 mg QD; (d) 5 mg QD and 5 mg BID; and (e) 2 and 5 mg BID.
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Table 3 Adjusted mean difference between dose regimens in FEV1 AUC0e12, AUC12e24 and AUC0e24 after 3 weeks of treatment.
Doses Adjusted mean difference (standard error) [95% CI]
FEV1 AUC0e12, L FEV1 AUC12e24, L FEV1 AUC0e24, L
5 mg QD vs 2 mg BID 0.054 (0.015)
[0.025, 0.083]
0.012 (0.015)
[0.041, 0.017]
0.022 (0.014)
[0.005, 0.049]
10 mg QD vs 5 mg QD 0.006 (0.015)
[0.034, 0.023]
0.006 (0.015)
[0.035, 0.024]
0.006 (0.014)
[0.033, 0.021]
5 mg QD vs 5 mg BID 0.021 (0.015)
[0.008, 0.050]
0.047 (0.015)
[0.076, 0.017]
0.013 (0.014)
[0.040, 0.014]
5 mg BID vs 2 mg BID 0.033 (0.015)
[0.004, 0.063]
0.035 (0.015)
[0.005, 0.064]
0.035 (0.014)
[0.007, 0.062]
Patients: 5 mg QD, n Z 47; 2 mg BID, n Z 46 (n Z 45; AUC0e12 and AUC0e24); 10 mg QD, n Z 46; 5 mg BID, n Z 46.
Table 4 Adjusted mean peak FEV1 response from 0 to 3 h and FEV1 trough response following 3 weeks of treatment.
Adjusted mean difference (standard error)
Doses Pre-dose FEV1, L
a Peak FEV1 from 0 to 3 h, L FEV1 at end of dosing interval, L
b
Baseline 1.202 (0.051) 1.276 (0.054) 1.165 (0.052)
2 mg BID 0.093 (0.028) 0.187 (0.029) 0.163 (0.062)
5 mg BID 0.129 (0.028) 0.230 (0.029) 0.197 (0.062)
5 mg QD 0.108 (0.028) 0.249 (0.029) 0.153 (0.062)
10 mg QD 0.087 (0.028) 0.242 (0.029) 0.150 (0.062)
Patients: 5 mg QD, nZ 47; 2 mg BID, nZ 45 (nZ 46; end of dosing interval); 10 mg QD, nZ 46; 5 mg BID, nZ 46, p < 0.001 (peak FEV1,
FEV1 at end of dosing interval) and p < 0.01 (trough FEV1) for all doses versus baseline.
a 10 min prior to dosing after 3 weeks.
b 23 h and 50 min post-dose after 3 weeks.
Figure 4 Adjusted mean FVC AUC0e24 for olodaterol QD (5 or
10 mg) or BID (2 or 5 mg) versus baseline after 3 weeks of
treatment.
612 G.F. Joos et al.for olodaterol 2 mg BID and 5 mg BID (assuming a linear dose
response between both) support the conclusions from the
observed data, thus indicating that olodaterol 2 mg was a
satisfactory dosing alternative to 2.5 mg in this study
(Fig. 5).
Other key comparisons of interest in this study were
between olodaterol 5 mg QD and dose regimens with double
the daily dose, either according to a QD (olodaterol 10 mg)
or BID (olodaterol 5 mg) regimen.
The 24-h bronchodilatory profile for olodaterol 5 mg QD
and 10 mg QD was nearly identical (Fig. 3c), suggesting that
both doses lie on the plateau of the QD doseeresponse
curve. A further comprehensive evaluation of the relative
efficacy of olodaterol 5 and 10 mg QD has now been con-
ducted in Phase III studies, and no significant difference in
efficacy between olodaterol 5 mg and olodaterol 10 mg has
been found [12e15]. The lack of washout period between
treatments may be considered a limitation in this study but
we believe that it is justified since any residual broncho-
dilatory effects from the previous treatment would not
have been present at the time of the 24-h pulmonary
function measurements at the end of each 3-week treat-
ment period. The benefits of conducting the trial in this
manner include reducing patient observation time and
maintaining the patient on active long-acting bronchodi-
lator therapy for the entire treatment period.
Doubling the total daily dose of olodaterol 5 mg QD can
also be achieved by adding an additional dose in the eve-
ning (i.e. olodaterol 5 mg BID). To our knowledge, this is the
Table 5 gMean plasma concentrations and gCV of olodaterol after 3 weeks of treatment.
Olodaterol 2 mg BID Olodaterol 5 mg QD Olodaterol 5 mg BID Olodaterol 10 mg QD
n gMean gCV, % n gMean gCV, % n gMean gCV, % n gMean gCV, %
Cpre,ss (pg/mL) e e e e e e 24 2.92 24.3 19 2.97 23.2
C0.167,ss (pg/mL) e e e 25 3.52 35.9 36 4.28 42.0 41 5.78 62.1
e, gMean and gCV not calculated as this parameter was available in less than one-third of treated patients.
gMean, geometric mean; gCV, geometric coefficient of variation.
Table 6 AEs by treatment following administration of olodaterol.
Olodaterol 2 mg
BID, n (%)
Olodaterol 5 mg
QD, n (%)
Olodaterol 5 mg
BID, n (%)
Olodaterol 10 mg
QD, n (%)
Total, n (%)
All AEs 11 (23.4) 11 (23.4) 13 (28.3) 9 (19.6) 29 (61.7)
Nasopharyngitis 1 (2.1) 1 (2.1) 3 (6.5) 3 (6.5) 6 (12.8)
Cough 0 (0.0) 1 (2.1) 0 (0.0) 2 (4.3) 3 (6.4)
Dyspnoea 0 (0.0) 3 (6.4) 1 (2.2) 0 (0.0) 3 (6.4)
Upper respiratory
tract infection
0 (0.0) 0 (0.0) 2 (4.3) 0 (0.0) 2 (4.3)
Dysphonia 0 (0.0) 1 (2.1) 0 (0.0) 2 (4.3) 2 (4.3)
Arthralgia 2 (4.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.3)
Muscle spasms 0 (0.0) 0 (0.0) 2 (4.3) 0 (0.0) 2 (4.3)
Fatigue 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.3) 2 (4.3)
Patients: 5 mg QD, n Z 47; 2 mg BID, n Z 47; 10 mg QD, n Z 46; 5 mg BID, n Z 46.
Once-daily vs twice-daily olodaterol in COPD 613first study with a QD bronchodilator that has directly
compared the 24-h FEV1 time profile of the same nominal
dose administered QD or BID. There are two points of in-
terest with such a comparison: firstly, to what extent does
the additional evening dose provide increased bronchodi-
lation during the 12 to 24-h interval; and secondly, does
increased bronchodilation at the time of morning adminis-
tration confer any advantage in terms of bronchodilation
during the 0 to 12-h interval.
With regard to the first question, the second 5 mg dose in
the evening resulted in an additional evening peak and an
increased degree of bronchodilation during the 12 to 24-h
period, reflected by an increase in FEV1 AUC12e24 response
for olodaterol 5 mg BID compared with olodaterol 5 mg QD.
When consideration is given to the typical 24-h timeprofile of
a QD bronchodilator (i.e. a peak bronchodilating effect
within 3 h post-dose, followed by a gradual decline over theTable 7 Drug-related AEs per treatment group (treated set).
Olodaterol 2 mg
BID, n (%)
Olodaterol 5 mg
QD, n (%)
All drug-related AEs 1 (2.1) 2 (4.3)
Cough 0 (0.0) 1 (2.1)
Dyspnoea 0 (0.0) 2 (4.3)
Fatigue 0 (0.0) 0 (0.0)
Dry throat 0 (0.0) 0 (0.0)
Dysphonia 0 (0.0) 0 (0.0)
Sensation of heaviness 1 (2.1) 0 (0.0)
Patients: 5 mg QD, n Z 47; 2 mg BID, n Z 47; 10 mg QD, n Z 46; 5 mg24-h dosing interval to trough valuesw 50% of peak values),
the 24-h FEV1 time profiles of olodaterol 5 mg QD and 5 mg BID
are likely representatives of a general characteristic of all QD
bronchodilators. However, we are not aware of any such
direct comparisons being conducted for other QD broncho-
dilators. A recent frequency study with indacaterol in pa-
tients with asthma evaluated the 24-h FEV1 time profile of
37.5 mg BID, 75 mg QD (registered dose for COPD in the USA)
and 150 mg QD, but did not include a 75 mg BID dosing
regimen. All studies with the QD anticholinergic tiotropium
have only used QD dosing regimens, with no studies including
a BID regimen. The BID anticholinergic aclidinium was first
developed according to a QD regimen, and later switched to
a BID dosing regimen after less than compelling efficacy
observed in Phase III trials for the QD regimen [17e19];
however, there are no studies that have directly compared
QD and BID dosing regimens of aclidinium.Olodaterol 5 mg
BID, n (%)
Olodaterol 10 mg
QD, n (%)
Total, n (%)
2 (4.3) 6 (13.0) 7 (14.9)
0 (0.0) 2 (4.3) 3 (6.4)
1 (2.2) 0 (0.0) 2 (4.3)
0 (0.0) 2 (4.3) 2 (4.3)
1 (2.2) 0 (0.0) 1 (2.1)
0 (0.0) 2 (4.3) 2 (4.3)
0 (0.0) 0 (0.0) 1 (2.1)
BID, n Z 46.
Figure 5 Adjusted mean FEV1 over time after 3 weeks
including interpolated data for the 2.5 mg BID profile.
614 G.F. Joos et al.While there was an increase in FEV1 at the end of the 24-
h interval for olodaterol 5 mg QD, this did not lead to an
increase in bronchodilation during the 0 to 12-h interval;
indeed, there was a small numerical increase in FEV1
AUC0e12 response for olodaterol 5 mg QD compared to olo-
daterol 5 mg BID. Overall, the average degree of broncho-
dilation for olodaterol 5 mg QD and olodaterol 5 mg BID was
similar.
The inclusion of two BID doses in the study offered a
first, albeit limited, comparison of the BID dose-response
profile of olodaterol. The observed separation of doses over
both the 0 to 12-h and 12 to 24-h intervals is consistent with
previous observations with olodaterol 2 mg and 5 mg QD,
suggesting that the dose response of olodaterol is similar
when administered according to either a QD or BID dosing
regimen.
Overall, systemic exposure to olodaterol was low
following treatment with olodaterol, with plasma concen-
tration assessments at some doses and time points being
below the lower limit of quantification. Urinary excretion
data, however, provided evidence that exposure was dose
proportional and comparable for a total daily dose irre-
spective of whether the study drug was administered as a
single dose or split into a BID dose. Treatment with oloda-
terol was well tolerated, with an acceptable safety profile.
In conclusion, all dose regimens of olodaterol (2 mg, 5 mg
BID; 5 mg, 10 mg QD) provided superior efficacy in FEV1 over
the 24-h dosing interval compared to baseline and were
well tolerated with no safety concerns. Overall, the study
provides further support for the efficacy of olodaterol 5 mg
QD in COPD, with a superior bronchodilatory profile
compared with olodaterol 2 mg BID, which is close to the
same total daily dose, and a similar degree of bronchodi-
lation over 24 h compared with double the daily dose
administered as either a QD (10 mg) or BID (5 mg) dosing
regimen.
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